MedTrace Logo

The DREAM (Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication) Trial

NCT00095654 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 5000

Last updated 2009-11-10

No results posted yet for this study

Summary

The purpose of this study is to determine if ramipril and/or rosiglitazone prevent the onset of type 2 diabetes.

Conditions

Interventions

DRUG

Ramipril

DRUG

Rosiglitazone

Sponsors & Collaborators

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • Aventis Pharmaceuticals

    collaborator INDUSTRY

  • GlaxoSmithKline

    collaborator INDUSTRY

  • King Pharmaceuticals is now a wholly owned subsidiary of Pfizer

    collaborator INDUSTRY

  • Wyeth is now a wholly owned subsidiary of Pfizer

    collaborator INDUSTRY

  • Gerstein, Hertzel, MD

    lead INDIV

Principal Investigators

  • Salim Yusuf, MD · McMaster University, FAX # 905-521-1166

  • Hertzel Gerstein, MD · McMaster University, FAX # 905-521-4967

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
FACTORIAL

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2001-07-31
Completion
2006-10-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00095654 on ClinicalTrials.gov